脉冲射频联合得保松治疗带状疱疹后神经痛的疗效观察

目的：观察脉冲射频调节联合得保松治疗带状疱疹后神经痛的疗效。方法：选择应用脉冲射频调节治疗带状疱疹后神经痛病人38例,脉冲射频调节联合得保松治疗组（A组）21例,单纯得保松治疗组（B组）17例。观察与记录患者治疗前、治疗后1周及治疗后3个月VAS评分,评定治疗效果优良率。结果：A组较B组VAS评分低（P〈0．01）,A组较B组优良率高（P〈0．01）,脉冲射频调节联合得保松治疗PHN,镇痛效果确切,有助于缓解患者症状、改善生活质量。结论：脉冲射频调节联合得保松治疗带状疱疹后神经痛效果安全有效。     

复方倍他米松联合5-氟尿嘧啶在增生性瘢痕中的应用效果分析

【摘要】 目的 对比分析复方倍他米松联合 5-氟尿嘧啶与单纯复方倍他米松注射治疗小面积增生性瘢痕的临床效果。方法 选取 2018年1月至2019 年7月毕节市第一人民医院收治的36例小面积增生性瘢痕患者作为研究对象, 按照随机数表法将其随机分为观察组与对照组, 每组18例。观察组患者采用复方倍他米松联合 5-氟尿嘧啶注射治疗, 对照组患者单纯采用复方倍他米松注射治疗, 对比观察两组患者温哥华瘢痕量表 (VSS) 评分及临床疗效。结果 治疗结束后1个月, 观察组患者VSS评分为 (2.00±0.77) 分, 明显低于对照组患者的VSS评分 (6.22±1.93) 分 (t = 8.616, P < 0.001); 随访1年后, 观察组患者中治愈8例、显效10例, 明显优于对照组患者的治愈3例、显效11例、无效4例 (Z = - 2.340, P = 0.019)。结论 与单纯应用复方倍他米松相比,应用复方倍他米松联合5-氟尿嘧啶治疗小面积增生性瘢痕可有效促进瘢痕组织消退, 改善瘢痕症状, 疗效更显著。     

皮损内注射治疗瘢痕疙瘩规律停药的临床研究

目的：探讨皮损内注射得宝松规律性停药对治疗瘢痕疙瘩临床效果的影响。方法：选择2007年1月-2014年12月期间到本院就诊的符合瘢痕疙瘩诊断的患者156例,采用随机数字表法将其分成A、B两组,A组为试验组共81例,B组为对照组共75例。A组在瘢痕疙瘩皮损内注射,采取逐渐减少浓度的方法规律停药;B组采用常规疗程停药方法。观察6个月,评估两组患者治疗效果及复发情况。结果：两组在治疗后1个月与治疗后6个月效果差异均无统计学意义（P>O.01）;治疗组复发率低于对照组,两组比较差异有统计学意义（P相似文献   

高频超声生物显微镜动态观察局部注射二丙酸倍他米松治疗病理性瘢痕

目的采用高频超声生物显微镜(HFB,40MHz)观察二丙酸倍他米松治疗病理性瘢痕的临床效果。方法对39例接受二丙酸倍他米松局部注射治疗患者(治疗组)和20例未接受任何治疗患者(对照组)以40MHz探头行高频超声,于第1、31、61、91天测量瘢痕横径、垂直厚度;以DFY型超声图像诊断仪测量其面积、平均灰度值、声强值;结合温哥华瘢痕量表(VSS)对瘢痕评分。结果治疗组:第31、61、91天较治疗前横径、垂直厚度明显减小(P均0.05),面积、平均灰度值、平均声强值明显减小(P均0.05),VSS评分明显降低(P均0.01);第61天较第31天、第91天较第61天以上各参数均明显减小(P0.05),评分明显降低(P0.01)。对照组:各参数及评分均降低,但差异无统计学意义(P均0.05)。结论高频超声显微镜能无创、定量观察二丙酸倍他米松局部治疗后病理性瘢痕改变,对评价治疗情况有一定临床价值。     

Treatment of distal ulcerative colitis with beclomethasone enemas: High therapeutic efficacy without endocrine side effects

Sixteen patients with 18 attacks of distal ulcerative colitis were treated randomly with either 0.5 mg topically administered beclomethasone dipropionate (BDP) or 5 mg betamethasone phosphate (BMT). The effect of the steroid enemas on adrenocortical function was examined by ACTH tests, which were performed before and 20 days after treatment. At completion of the trial, a marked suppression of the adrenocortical function was found in seven of eight patients treated for nine attacks with BMT but not in any patients in the BDP group (P<0.01). The mean posttreatment basal and stimulated plasma cortisol levels in the BMT group were significantly lower as compared with the BDP group. The overall therapeutic response assessed by score systems was comparable in the two treatment groups. It is concluded that, in the topical treatment of ulcerative colitis, BDP is preferable to BMT because it exerts an equal anti-inflammatory action without affecting adrenocortical function.     

Effects into adulthood of single or repeated antenatal corticosteroids in sheep

OBJECTIVE: To determine effects of maternal or fetal injections of betamethasone on postnatal growth and arterial pressure. STUDY DESIGN: We measured body weight, arterial pressure, and heart rate serially in sheep born after single or repeated maternal or fetal betamethasone injections. At approximately 3.5 years, organ weights were measured. RESULTS: Repeated maternal betamethasone injections caused intrauterine growth restriction, and low body weight and blood pressure at 3 months. From 6 months to 3 years, body weight, blood pressure, and heart rate were not affected by treatment. At approximately 3.5 years, brain weight was reduced after single or repeated maternal betamethasone by 13% and 18%, respectively (P = .001). Fetal betamethasone reduced brain weight by 7% to 8% (P = .018). Weights of other organs were not affected by treatment. Brain weight was unrelated to body weight at approximately 3.5 years (P = .649) but was related to birth weight (P = .029). CONCLUSION: Prenatal betamethasone does not have long-term effects on blood pressure but causes a persistent deficit in brain weight.     

Choice and dose of corticosteroid for antenatal treatments

Although antenatal glucocorticoids are standard of care for women at risk of preterm delivery before 32 to 34 weeks' gestation, the choice and dosing of the corticosteroid has not been standardized. An analysis of the trial data demonstrates that the risk of neonatal death is decreased with betamethasone, but not dexamethasone. Other clinical data also indicate that betamethasone is the drug of choice for antenatal treatment. The pharmacology of the corticosteroids suggests that a lower total glucocorticoid dose per treatment may be as effective as the current treatment recommendations. However, a change from current practice will require further randomized controlled trials.     

地塞米松与倍他米松对大鼠胎肺形态发育影响的对比

目的 比较产前小剂量应用地塞米松、倍他米松对大鼠胎肺形态发育的影响.方法 15只孕鼠随机分成对照组、地塞米松治疗1 d组、3 d组和倍他米松治疗1 d组及3 d组,每组3只.地塞米松及倍他米松3 d组分别于妊娠第16、17、18天连续腹腔注射地塞米松或倍他米松,剂量为0.2 mg/(kg·d);地塞米松及倍他米松1 d组于妊娠第16、17天腹腔注射4 m1生理盐水,妊娠第18天给予相应剂量药物.对照组大鼠于妊娠第16、17、18天连续注射4 ml生理盐水.光镜及电镜观察各组孕鼠的胎仔肺组织形态发育变化. 结果 (1)与对照组相比,倍他米松3 d、1 d组及地塞米松3 d组肺泡结构发育较为成熟.(2)倍他米松3 d组的肺泡间隔为(23.38±7.77)μm,地塞米松3 d组为(30.82±5.32)μm,倍他米松1 d组为(33.37±9.30)μm,均小于对照组[(71.15±48.72)μm](P＜0.01);倍他米松1 d组的呼吸膜周径为(43.24±18.20)μm、肺泡表面积为(412.71±298.45)μm2,倍他米松3 d组分别为(61.22±23.58)μm和(780.23±428.34)μm2,地塞米松3 d组分别为(40.31±15.20)μm和(471.08±324.63)μm2,均大于对照组[分别为(32.06±11.40)μm和(285.70土175.77)μm2](P＜0.01);倍他米松1 d组与地塞米松1 d组相比肺泡间隔薄,呼吸膜周径及肺泡表面积增大(P＜0.01).倍他米松3 d组与地塞米松3 d组相比肺泡间隔薄(P＜0.01),呼吸膜周径及肺泡表面积增大(P＜0.01).(3)透射电镜观察发现,倍他米松1 d、3 d及地塞米松3 d组肺泡Ⅱ型上皮细胞内可见板层小体,以倍他米松和地塞米松3 d组改变最为明显,而对照组未见板层小体.结论 小剂量地塞米松、倍他米松均能促进胎肺发育,但倍他米松效果更好.     

Actualización del tratamiento tópico en psoriasis: aportación de la combinación de calcipotriol y dipropionato de betametasona en espuma

Topical agents are the first-line treatment for mild and moderate psoriasis, but factors such as frequency of administration, organoleptic properties, and the limited short term results can reduce treatment adherence and effectiveness.Innovations in topical treatments are linked not only to the discovery of new molecules, but also to the reformulation of existing active ingredients based on improvements to administration, organoleptic properties, bioavailability, and ease of use. Calcipotriol and betamethasone dipropionate aerosol foam is a new formulation in which the active ingredients are dissolved in a mixture of volatile propellants that evaporate quickly, leaving a supersaturated solution of calcipotriol and betamethasone dipropionate that enhances penetration into the epidermis.In this article, we take a look at the new calcipotriol and betamethasone dipropionate aerosol formulation and briefly review the main evidence supporting the use of topical treatments for psoriasis.     

Comparison of 0.1 % Halcinonide with 0.05 % Betamethasone Dipropionate in the Treatment of Acute and Chronic Dermatoses

Summary

A 4-Week, Bilateral, Controlled Study Was Carried Out In 53 Patients With Various Acute And Chronic Dermatoses To Compare The Effectiveness Of 0.1% Halcinonide In A Water-Miscible Base, Applied Once Daily, With 0.05% Betamethasone Dipropionate Cream Applied Twice Daily. Patients' Response To Treatment Was Assessed At The End Of Each Week. Halcinonide Proved To Be Equally As Effective As Betamethasone Dipropionate In Most And Superior In Some Patients With Psoriasis, Lichen Chronicus Simplex, And Atopic And Neurodermatitis. There Was Also A Prompt Response To Once Daily Treatment With Halcinonide Inpatients With contact Dermatitis, Eczema Of The Hands, And More Serious Cases Of Eczema Nummular E And Allergic Skin Reactions, Many Of Whom Had Failed To Respond To Previous Topical Steroid Therapy. Both Preparations Were Well Tolerated And Side-Effects Were Noted In Only 1 Patient With Psoriasis Whose Condition Was Aggravated By Halcinonide. Only 3 Patients Had A Relapse During The 1-Month Follow-Up Period After Treatment Was Stopped.